Helomics AI cancer lab acquisition drives continued MEDS premarket momentum

 

• DataMEDS completed acquisition of Helomics from Axe Compute (AGPU) on Sep 15 for $1.5M in shares/note.
• Deal adds CLIA/CAP-certified oncology lab, Predictive Oncology CRO services, equipment, and $1.5M cash with no debt.
• Helomics brings AI-driven cancer diagnostics and tumor profiling, expanding MEDS from chronic care into $40B oncology market.
• Stock exploded 87% on Sep 15 and 275% on Sep 16 (close $6.07) on massive volume exceeding 188M shares.
• Premarket Sep 17 shows 16-22% gains to ~$7.00-$7.40 range, reflecting ongoing retail momentum in this low-float name.
• Management cited rural cancer care focus and integration with existing Health Lives Here platform and pharmacy network.

https://finviz.com/stock?t=MEDS&p=d